JP2011523550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523550A5 JP2011523550A5 JP2011508949A JP2011508949A JP2011523550A5 JP 2011523550 A5 JP2011523550 A5 JP 2011523550A5 JP 2011508949 A JP2011508949 A JP 2011508949A JP 2011508949 A JP2011508949 A JP 2011508949A JP 2011523550 A5 JP2011523550 A5 JP 2011523550A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- acid sequences
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 80
- 150000001413 amino acids Chemical class 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 14
- 102000053523 human CXCR4 Human genes 0.000 claims 14
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 102000043525 human CXCL12 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 235000002198 Annona diversifolia Nutrition 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 241000282838 Lama Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002975 chemoattractant Substances 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5384708P | 2008-05-16 | 2008-05-16 | |
| US61/053,847 | 2008-05-16 | ||
| US10214208P | 2008-10-02 | 2008-10-02 | |
| US61/102,142 | 2008-10-02 | ||
| PCT/EP2009/056026 WO2009138519A1 (en) | 2008-05-16 | 2009-05-18 | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523550A JP2011523550A (ja) | 2011-08-18 |
| JP2011523550A5 true JP2011523550A5 (enExample) | 2013-06-13 |
| JP6034023B2 JP6034023B2 (ja) | 2016-11-30 |
Family
ID=40974643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508949A Active JP6034023B2 (ja) | 2008-05-16 | 2009-05-18 | Ｃｘｃｒ４及び他のｇｐｃｒに指向性を有するアミノ酸配列及びそれを含む化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9212226B2 (enExample) |
| EP (1) | EP2285833B1 (enExample) |
| JP (1) | JP6034023B2 (enExample) |
| KR (1) | KR20110020825A (enExample) |
| CN (1) | CN102099378B (enExample) |
| AU (1) | AU2009248049B2 (enExample) |
| BR (1) | BRPI0911984A2 (enExample) |
| CA (1) | CA2724208C (enExample) |
| IL (1) | IL209176A0 (enExample) |
| MX (1) | MX2010012518A (enExample) |
| NZ (1) | NZ589036A (enExample) |
| RU (1) | RU2010151725A (enExample) |
| WO (1) | WO2009138519A1 (enExample) |
| ZA (1) | ZA201008180B (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| WO2012130874A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| AU2009248049B2 (en) | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| EP2352764B1 (en) * | 2008-10-14 | 2018-03-28 | Ablynx N.V. | AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY |
| DK2370465T3 (da) | 2008-12-19 | 2019-05-06 | Ablynx Nv | Genetisk immunisering til fremstilling af immunoglobuliner mod celleassocierede antigener, såsom p2x7, cxcr7 eller cxcr4 |
| US20110117113A1 (en) | 2009-10-09 | 2011-05-19 | Gerald Beste | Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them |
| WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
| US8937164B2 (en) | 2010-03-26 | 2015-01-20 | Ablynx N.V. | Biological materials related to CXCR7 |
| EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
| WO2011161266A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4 |
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| JP5933573B2 (ja) * | 2010-11-08 | 2016-06-15 | ノバルティス アーゲー | Ｃｘｃｒ２結合ポリペプチド |
| FR2970781B1 (fr) * | 2011-01-25 | 2013-02-08 | Centre Nat Rech Scient | Procede de fabrication d'un support d'analyse et utilisation pour la detection de toxines |
| UA117218C2 (uk) * | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| PT2723764T (pt) | 2011-06-21 | 2018-03-09 | Univ Leland Stanford Junior | Domínios de ligação dirigidos contra complexos gpcr:proteína g e suas utilizações derivadas |
| PH12022550313A1 (en) | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP4350345A3 (en) | 2011-06-23 | 2024-07-24 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| EP3466972B1 (en) | 2011-06-23 | 2026-03-04 | Ablynx NV | Serum albumin binding proteins |
| RS55775B2 (sr) | 2011-06-23 | 2022-10-31 | Ablynx Nv | Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina |
| ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
| CN106046161B (zh) | 2011-09-30 | 2019-09-13 | 埃博灵克斯股份有限公司 | 与C-Met相关的生物物质 |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| HRP20220253T1 (hr) * | 2011-10-17 | 2022-04-29 | Regeneron Pharmaceuticals, Inc. | Miševi s ograničenim teškim lancem imunoglobulina |
| US9328174B2 (en) * | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| US11339208B1 (en) | 2012-05-31 | 2022-05-24 | United States Of America As Represented By The Secretary Of The Air Force | Camelidae single-domain antibodies against Yersinia pestis and methods of use |
| CN102993295A (zh) * | 2012-09-29 | 2013-03-27 | 张文彬 | 双峰驼褪黑素受体、编码基因及其获取方法 |
| UY35144A (es) * | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| WO2015026884A1 (en) * | 2013-08-21 | 2015-02-26 | Boehringer Ingelheim International Gmbh | Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| DK3143403T3 (da) | 2014-05-16 | 2022-01-17 | Ablynx Nv | Fremgangsmåder til påvisning og/eller måling af anti-lægemiddelantistoffer, især behandlingsinducerede anti-lægemiddelantistoffer |
| KR20250099289A (ko) * | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| WO2016156570A1 (en) | 2015-04-02 | 2016-10-06 | Ablynx N.V. | Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity |
| NO2768984T3 (enExample) | 2015-11-12 | 2018-06-09 | ||
| LT3374392T (lt) | 2015-11-13 | 2022-01-25 | Ablynx Nv | Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai |
| CR20180279A (es) | 2015-11-18 | 2018-08-24 | Merck Sharp & Dohme | Enlazadores de ctla4 |
| SG11201804178YA (en) | 2015-11-18 | 2018-06-28 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| WO2017085172A2 (en) | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
| KR20180083418A (ko) | 2015-11-18 | 2018-07-20 | 머크 샤프 앤드 돔 코포레이션 | Pd1/ctla4 결합제 |
| CN108699151B (zh) | 2016-02-12 | 2022-08-12 | 埃博灵克斯股份有限公司 | 用于制备免疫球蛋白单可变结构域的方法 |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| CN109313183B (zh) | 2016-06-23 | 2022-10-21 | 埃博灵克斯股份有限公司 | 免疫球蛋白单可变结构域的改进的药代动力学测定 |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| IL310340A (en) | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| MX2019008536A (es) | 2017-01-17 | 2019-09-10 | Ablynx Nv | Aglutinantes de albumina serica mejorados. |
| KR102662499B1 (ko) | 2017-01-17 | 2024-05-02 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| CN110546506B (zh) * | 2017-03-31 | 2023-04-04 | 埃博灵克斯股份有限公司 | 改进的免疫原性测定法 |
| TWI818938B (zh) * | 2017-12-19 | 2023-10-21 | 南韓商Ｇｐｃｒ醫療公司 | Gpcr異聚體抑制劑及其用途 |
| SMT202100307T1 (it) | 2018-01-26 | 2021-07-12 | Regeneron Pharma | Anticorpi e frammenti di legame di anti-tmprss2 |
| CN113416258B (zh) * | 2019-10-24 | 2023-08-29 | 北京免疫方舟医药科技有限公司 | 一种多特异性抗体及其制备方法和用途 |
| JP7772702B2 (ja) | 2020-02-10 | 2025-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｔｍｐｒｓｓ２抗体および抗原結合断片 |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| WO2021242815A1 (en) | 2020-05-26 | 2021-12-02 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| CN111596070B (zh) * | 2020-06-10 | 2023-05-12 | 宁波大学 | 一种三疣梭子蟹原肌球蛋白过敏检测试剂的应用 |
| WO2022187626A1 (en) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments |
| CA3225575A1 (en) | 2021-07-14 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| WO2023155902A1 (en) | 2022-02-18 | 2023-08-24 | Chongqing Mingdao Haoyue Biotechnology Co., Ltd. | Intranasal formulations and anti-sars-cov-2-spike protein antibodies |
| JP2025526384A (ja) | 2022-07-27 | 2025-08-13 | アブリンクス エン．ヴェー． | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |
| EP4608859A1 (en) | 2022-10-25 | 2025-09-03 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| CN115960269A (zh) * | 2023-01-30 | 2023-04-14 | 上海甲贝医药科技有限公司 | 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法 |
| EP4665755A1 (en) | 2023-02-17 | 2025-12-24 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| TW202448951A (zh) | 2023-05-17 | 2024-12-16 | 美商奧迪希治療公司 | 經修飾之單域抗體 |
| TW202515917A (zh) | 2023-06-29 | 2025-04-16 | 美商奧迪希治療公司 | 抗trailr2抗原結合蛋白及其用途 |
| WO2025008537A1 (en) | 2023-07-05 | 2025-01-09 | Ablynx Nv | Improved fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025041077A1 (en) | 2023-08-23 | 2025-02-27 | Sanofi | Ctla-4-based lysosomal degraders and uses thereof |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| WO2025088546A1 (en) | 2023-10-25 | 2025-05-01 | Ablynx N.V. | Fc domain variants with enhanced fc receptor binding |
| AR134267A1 (es) | 2023-11-08 | 2025-12-17 | Sanofi Sa | Degradador lisosómico basado en cd25 y usos del mismo |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
| WO2026006708A2 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2026006809A1 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Multispecific molecules binding tnfr2 and cd25 and uses thereof |
| CN120818528B (zh) * | 2025-07-14 | 2026-02-10 | 贵州大学 | 萝卜RsBBX9基因在调控花青素合成中的应用及方法 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| DE69318016D1 (de) | 1992-05-08 | 1998-05-20 | Creative Biomolecules Inc | Mehrwertige Chimäre Proteine Anologe und Verfahren zu deren Anwendungen |
| AU740043B2 (en) | 1996-06-27 | 2001-10-25 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
| AU766675B2 (en) * | 1998-03-30 | 2003-10-23 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| WO2000043507A1 (en) | 1999-01-19 | 2000-07-27 | Unilever Plc | Method for producing antibody fragments |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| ES2270893T3 (es) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos. |
| CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US7018812B2 (en) * | 2000-11-03 | 2006-03-28 | Duke University | Modified G-protein coupled receptors |
| US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| AU2002351896A1 (en) | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| AU2002360068B2 (en) | 2001-12-21 | 2009-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
| JP2005517674A (ja) | 2002-01-03 | 2005-06-16 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 腫瘍の処置に有用な新規免疫コンジュゲート |
| AU2003209059A1 (en) * | 2002-02-08 | 2003-09-02 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
| ATE554390T1 (de) | 2003-08-20 | 2012-05-15 | Ucb Pharma Sa | Verfahren zur gewinnung von antikörpern |
| US20050279676A1 (en) | 2004-06-21 | 2005-12-22 | Izzy Zuhair A | Fluid filter assembly for a dispensing faucet |
| EP4353819A3 (en) | 2004-07-22 | 2024-07-17 | Erasmus University Medical Center Rotterdam | Binding molecules |
| US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
| WO2006040154A2 (en) | 2004-10-14 | 2006-04-20 | Dublin City University | Prokaryotic two hybrid system |
| WO2006047417A2 (en) | 2004-10-21 | 2006-05-04 | University Of Florida Research Foundation, Inc. | Detection of cannabinoid receptor biomarkers and uses thereof |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US8329178B2 (en) * | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| ES2434852T3 (es) | 2005-04-21 | 2013-12-17 | Chemocentryx, Inc. | Anticuerpos que se unen a CCX-CKR2 |
| JP2009511032A (ja) * | 2005-10-11 | 2009-03-19 | アブリンクス エン．ヴェー． | Ｅｇｆｒおよびｉｇｆ−ｉｒに対するナノボディおよびポリペプチド |
| WO2007055823A2 (en) | 2005-10-28 | 2007-05-18 | Multispan, Inc. | Gpcr expressing cell lines and antibodies |
| WO2007059108A2 (en) | 2005-11-10 | 2007-05-24 | Chemocentryx, Inc. | Substituted quinolones and methods of use |
| EP2010568A1 (en) | 2006-04-14 | 2009-01-07 | Ablynx N.V. | Dp-78-like nanobodies |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| US8088895B2 (en) | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| WO2012130874A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| AU2007336242B2 (en) * | 2006-12-19 | 2012-08-30 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| AU2009248049B2 (en) | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| CA2731617A1 (en) | 2008-07-22 | 2010-01-28 | Maria Joao Saraiva | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
| EP2352764B1 (en) | 2008-10-14 | 2018-03-28 | Ablynx N.V. | AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY |
| DK2370465T3 (da) | 2008-12-19 | 2019-05-06 | Ablynx Nv | Genetisk immunisering til fremstilling af immunoglobuliner mod celleassocierede antigener, såsom p2x7, cxcr7 eller cxcr4 |
| WO2010141986A1 (en) | 2009-06-09 | 2010-12-16 | Mabdesign Pty Ltd | Novel antibodies and uses therefor |
| US8937164B2 (en) | 2010-03-26 | 2015-01-20 | Ablynx N.V. | Biological materials related to CXCR7 |
| WO2011143231A2 (en) | 2010-05-10 | 2011-11-17 | The Broad Institute | High throughput paired-end sequencing of large-insert clone libraries |
-
2009
- 2009-05-18 AU AU2009248049A patent/AU2009248049B2/en active Active
- 2009-05-18 WO PCT/EP2009/056026 patent/WO2009138519A1/en not_active Ceased
- 2009-05-18 NZ NZ589036A patent/NZ589036A/en not_active IP Right Cessation
- 2009-05-18 BR BRPI0911984A patent/BRPI0911984A2/pt not_active IP Right Cessation
- 2009-05-18 JP JP2011508949A patent/JP6034023B2/ja active Active
- 2009-05-18 RU RU2010151725/10A patent/RU2010151725A/ru not_active Application Discontinuation
- 2009-05-18 US US12/992,982 patent/US9212226B2/en active Active
- 2009-05-18 CN CN200980127612.4A patent/CN102099378B/zh active Active
- 2009-05-18 CA CA2724208A patent/CA2724208C/en active Active
- 2009-05-18 EP EP09745851.7A patent/EP2285833B1/en active Active
- 2009-05-18 KR KR1020107028173A patent/KR20110020825A/ko not_active Withdrawn
- 2009-05-18 MX MX2010012518A patent/MX2010012518A/es not_active Application Discontinuation
-
2010
- 2010-11-07 IL IL209176A patent/IL209176A0/en unknown
- 2010-11-15 ZA ZA2010/08180A patent/ZA201008180B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523550A5 (enExample) | ||
| JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
| RU2010151725A (ru) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их | |
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2020500510A5 (enExample) | ||
| JP4294596B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| CN106604932B (zh) | 人白细胞介素-2的免疫刺激单克隆抗体 | |
| CN111606993B (zh) | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 | |
| JP2012518425A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2022046510A (ja) | 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン | |
| JP2011521662A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP6587609B2 (ja) | 強皮症治療のための抗ｃｃｌ２及び抗ｌｏｘｌ２併用療法 | |
| JP2010511388A5 (enExample) | ||
| CN111201246A (zh) | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 | |
| CN109311983B (zh) | 人源化抗clever-1抗体及其用途 | |
| JP2019506839A5 (enExample) | ||
| JP2021534727A (ja) | Ｓｆｔｓｖに結合可能なナノ抗体及びその使用 | |
| JP2012524524A5 (enExample) | ||
| WO2013178783A1 (en) | P2x7 receptor antagonists and agonists | |
| JP2013511996A5 (enExample) | ||
| JP2017529870A5 (enExample) | ||
| CN116075524A (zh) | 转铁蛋白受体结合蛋白 | |
| Aoki et al. | Engineering a low-immunogenic mirror-image VHH against vascular endothelial growth factor |